Suparna Jain
Pediatric Endocrinology · Santa Monica, CANPI 1053536458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,741 of the $9,994 with a category attached, or 67.5%. Ascendis Pharma Endocrinology Inc accounts for 84.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $8,124 and has fallen 95.1% since, to $402 in 2025.
Across 97 payments — averaging $103.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$8K
- AbbVie$427
- Tolmar Pharmaceuticals, Inc.$266
- Soleno Therapeutics, Inc.$157
- Pfizer$132
- Endo Pharmaceuticals Inc.$83
- plus $512 from 15 others
Across 27 payments — averaging $91.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
What the payments were for
- Speaking & faculty fees$6,74167%
- Travel & lodging$8609%
- Food & beverage$2,35924%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 21 | $8,418 |
| AbbVie | 20 | $427 |
| Tolmar Pharmaceuticals, Inc. | 21 | $266 |
| Soleno Therapeutics, Inc. | 5 | $157 |
| Pfizer | 5 | $132 |
| Endo Pharmaceuticals Inc. | 4 | $83 |
| Arbor Pharmaceuticals, Inc. | 4 | $81 |
| Sandoz | 2 | $58 |
| Tolmar, Inc. | 2 | $56 |
| Novo Nordisk | 2 | $47 |
| Tandem Diabetes Care, Inc. | 1 | $43 |
| Neurocrine Biosciences, Inc. | 1 | $38 |
| GSK | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Sobi, Inc | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $14 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SKYTROFA$149
How this compares
$9,994 in reported general payments places this provider in the 85th percentile of 168 pediatric endocrinology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 12 | $40,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerGenotropin | $132 | $40,43612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Santa Monica
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Amrit BhangooLong Beach$140K
- Mitchell GeffnerLos Angeles$129K
- Stephen GitelmanSan Francisco$105K
- David MaahsStanford$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.